---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042251"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:47:14.642311+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing

## Summary
- Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.
- BayMedica revenue $1.26M (+8% YoY); gross margin declined due to pricing pressure.
- Cash and equivalents $4.68M (Jun 30, 2024: $6.57M); expects to fund operations into Q3 2025.
- R&D expenses $0.91M vs $0.65M YoY, driven by INM-901 and INM-089 programs.
- Company seeks additional financing through equity, debt, or collaborations to fund pipeline.

## SEC filing metadata
- accession: 0001213900-25-042251
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/0001213900-25-042251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/ea0241856-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042251
- JSON: https://secwatch.observer/filing/0001213900-25-042251.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.